DBV Technologies (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. The firm presently has a $26.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 12.70% from the stock’s previous close.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other research analysts also recently commented on DBVT. BidaskClub upgraded DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday. Deutsche Bank set a $33.00 price target on DBV Technologies and gave the stock a “buy” rating in a research note on Tuesday, March 27th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Thursday, March 15th. Finally, Citigroup set a $57.00 price target on DBV Technologies and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $46.00.
Large investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new position in DBV Technologies during the 3rd quarter worth approximately $2,190,000. Emory University grew its stake in shares of DBV Technologies by 113.4% in the 4th quarter. Emory University now owns 81,916 shares of the company’s stock valued at $2,015,000 after purchasing an additional 43,535 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of DBV Technologies in the 4th quarter valued at approximately $662,000. Citadel Advisors LLC grew its stake in shares of DBV Technologies by 57.3% in the 4th quarter. Citadel Advisors LLC now owns 288,879 shares of the company’s stock valued at $7,106,000 after purchasing an additional 105,224 shares during the last quarter. Finally, GW&K Investment Management LLC grew its stake in shares of DBV Technologies by 38.9% in the 4th quarter. GW&K Investment Management LLC now owns 138,391 shares of the company’s stock valued at $3,404,000 after purchasing an additional 38,725 shares during the last quarter. Hedge funds and other institutional investors own 45.68% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades DBV Technologies (DBVT) to “Buy”” was published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2018/04/01/zacks-investment-research-upgrades-dbv-technologies-dbvt-to-buy.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.